Status reference — not a product page. Cora Health does not sell Emideltide.
Emideltide (DSIP): is it legal in 2026?
No — and it is not an FDA-approved drug.
Emideltide is not on the FDA's Section 503A bulks list, and no rulemaking that could change that has been completed. The HHS interim enforcement policy published October 30, 2026 does not cover it. On July 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted against adding it to that list — and a committee rejection is not an FDA final decision either. Cora Health does not sell, prescribe, or compound Emideltide.
PCAC status
Rejected by PCAC — voted against inclusion on the 503A bulks list, 6-7-1, 2026-07-24 (the committee's only rejection)
Compounding status today
No — not on the FDA 503A bulks list; no final rule; not covered by the HHS interim enforcement policy
FDA-approved drug
No
Description and uses on FDA's agenda
Delta sleep-inducing peptide (DSIP); the uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy
Human clinical data
Limited — intravenous doses given to 209 subjects for 1 to 15 days, with adverse effects reported in some studies, and no safety data for the proposed subcutaneous route; FDA cited a lack of safety and efficacy data and inadequate characterization; one meeting participant said the last study was roughly 30 years old
WADA status
Not named on the WADA 2026 Prohibited List; that does not by itself mean it is permitted
Last verified 2026-11-02 · Status Index v1.5.0 · CC-BY-4.0
Where Emideltide actually stands
Emideltide, also called delta sleep-inducing peptide (DSIP), is the one peptide of the seven that the FDA's Pharmacy Compounding Advisory Committee voted AGAINST in July 2026. The uses the FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy. FDA staff's briefing document describes intravenous doses given to 209 subjects for 1 to 15 days, with adverse effects reported in some studies, and no safety data for the proposed subcutaneous route; FDA cited a lack of safety and efficacy data, inadequate characterization of the substance, and existing approved therapies for the proposed uses, and one meeting participant said the last study was roughly 30 years old. On July 24, 2026 the committee voted 6-7-1 against adding it to the Section 503A bulks list.
How Emideltide got here, and what comes next
Emideltide was not recommended. It is outside the HHS interim enforcement policy, which covers only the six peptides that were.
-
June 30, 2026
FDA staff review reported — recommends against listing all seven
As reported on June 30, 2026, FDA career scientists highlighted safety risks and what they described as little evidence of benefit, and recommended against adding any of the seven peptides to the 503A bulks list.
-
July 24, 2026
PCAC day two — three peptides evaluated, one rejected
The committee recommended Semax (8-5) and Epitalon (7-5-1), and voted against Emideltide, also called DSIP (6-7-1) — the meeting's only rejection, and its only vote that agreed with FDA staff. Six of seven recommended across the two days.
-
October 30, 2026
HHS publishes an interim enforcement policy for six of the seven
Filed October 28 and published October 30, 2026 (91 FR 68526). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500, each in a specified form and route, when all 10 conditions are met, until a final rule addresses that peptide. The notice calls the policy a draft that is not binding on HHS or the public and takes comments until November 13, 2026. It is not FDA approval and it adds nothing to the 503A bulks list. Emideltide (DSIP) is not covered.
-
Next step — no date
A final rule on each peptide
Adding any substance to the 503A bulks list still requires a full rulemaking — a proposed rule, a public comment period, and a final rule the agency can decline to issue. The HHS interim policy runs until a final rule addresses each peptide as included or not included, and HHS may revisit it sooner. We are not attaching a date to this, and no one credibly can. This entry updates when the rule or the policy changes.
Emideltide, question by question
Is Emideltide FDA-approved?
No. Emideltide is not an FDA-approved drug. It has not been through the FDA drug-approval process, so the FDA has not established that it is safe or effective, and neither the July 2026 advisory committee vote nor the HHS interim enforcement policy changed that — the committee voted against recommending it, an advisory vote in either direction is not an FDA decision, and the HHS policy does not cover it.
Is Emideltide legal to compound in 2026?
No. Emideltide is not on the FDA's Section 503A bulks list, no rulemaking has added it, and the HHS interim enforcement policy published October 30, 2026 does not cover it.
What did the FDA advisory committee decide about Emideltide?
Rejected by PCAC — voted against inclusion on the 503A bulks list, 6-7-1, 2026-07-24 (the committee's only rejection). PCAC voted against adding Emideltide to the 503A bulks list, aligning with FDA staff, who cited a lack of safety and efficacy data, inadequate characterization, and existing FDA-approved therapies for the proposed uses. Not an FDA final decision either way. Emideltide is not covered by the HHS interim enforcement policy.
What human clinical evidence exists for Emideltide?
Limited — intravenous doses given to 209 subjects for 1 to 15 days, with adverse effects reported in some studies, and no safety data for the proposed subcutaneous route; FDA cited a lack of safety and efficacy data and inadequate characterization; one meeting participant said the last study was roughly 30 years old. Delta sleep-inducing peptide (DSIP); the uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy. The evidence base for these peptides is thin, and nothing here is a claim that Emideltide works. Compounded medications are not FDA-approved.
Does Cora Health sell Emideltide?
No. Cora Health does not sell, prescribe, or compound Emideltide. Cora does not prescribe medication at all — licensed providers at Wasef Health, PC make every prescribing decision, and the compounded medications available through Cora Health are prepared by US-licensed 503A compounding pharmacies, including Hallandale Pharmacy and VialsRx. Compounded medications are not FDA-approved.
Every fact on this page traces to the sources below. Where a fact could not be located in them, the field says so rather than asserting one. See an error? Email help@trycora.io — corrections ship with a dataset version bump.
- FDA staff briefing document, July 2026 PCAC meeting — Emideltide — https://www.fda.gov/media/193344/download (fetched 2026-11-02)
- WADA — International Standard Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (fetched 2026-11-02)
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (fetched 2026-11-02)
- FDA — Pharmacy Compounding Advisory Committee (PCAC) — https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee (fetched 2026-07-25)
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca (fetched 2026-07-25)
- FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 (fetched 2026-07-25)
- Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 — https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/ (fetched 2026-06-30)
- RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list, 2026-07-24 — https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html (fetched 2026-07-25)
Not FDA-approved. Emideltide is not an FDA-approved drug and is not on the FDA's Section 503A bulks list. A PCAC recommendation is non-binding advice the FDA can decline, and a PCAC rejection is not an FDA final decision either. Nothing on this page is a claim that Emideltide is safe or effective.
Cora Health does not sell, prescribe, or compound Emideltide. Cora Health is a telehealth platform that connects patients with licensed independent providers at Wasef Health, PC, who make all prescribing decisions. The compounded medications available through Cora, including compounded semaglutide and compounded tirzepatide, are prepared by 503A compounding pharmacies, including Hallandale Pharmacy (a PCAB-accredited 503A compounding pharmacy) and VialsRx (a US-licensed 503A compounding pharmacy). Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.
General information, not medical or legal advice.